PROTEIN CYSTEIC ACID AS A BIOMARKER OF OXIDATIVE STRESS

蛋白质磺基丙氨酸作为氧化应激的生物标志物

• 批准号: 2592947
• 负责人: JOSEPH M KINKADE
• 金额: $ 7.73万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-01-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2592947
• 关键词: antioxidants; biomarker; blood chemistry; clinical research; coronary disorder; cysteine; enzyme linked immunosorbent assay; epidemiology; human subject; inflammation; kidney disorder; method development; monoclonal antibody; oxidation; oxidative stress

DESCRIPTION The long-term goal of this research is to identify mechanisms underlying oxidative damage in human diseases associated with inflammation and oxidative stress. Cysteine and cystine residues in proteins can be oxidized to cysteic acid by strong oxidants encountered in the environment. Currently, there are no fully validated biomarkers for assessing oxidative stress or antioxidant interventions in humans. This project will test the hypothesis that protein cysteic acid can be used to measure the severity and/or duration of in vivo oxidative stress. There are two aims: 1) To prepare a monoclonal antibody against cysteic acid that will recognize this epitope/biomarker in plasma proteins and to develop an ELISA assay for quantification of the biomarker, 2) To use the ELISA assay to assess variability in basal plasma levels of the biomarker and its association with coronary artery and renal disease, conditions that are related to inflammation and oxidative stress. Completion of these specific aims will provide a novel biomarker for population-based molecular epidemiologic studies. Such studies will provide information aimed at the prevention and control of human diseases associated with inflammation and oxidative stress that may occur in environmental disease.

描述 这项研究的长期目标是确定潜在的机制 与炎症相关的人类疾病中的氧化损伤 氧化应激。 蛋白质中的半胱氨酸和胱氨酸残基可以被氧化 环境中遇到强氧化剂会分解为磺基丙氨酸。 目前，还没有经过充分验证的生物标志物来评估氧化 人类的压力或抗氧化干预。 该项目将测试 假设蛋白质磺基丙氨酸可用于衡量严重程度 和/或体内氧化应激的持续时间。 有两个目标：1） 制备能够识别这一点的抗磺基丙氨酸单克隆抗体 血浆蛋白中的表位/生物标志物，并开发 ELISA 检测方法 生物标志物的定量，2) 使用 ELISA 测定来评估 生物标志物基础血浆水平的变异性及其与 冠状动脉和肾脏疾病以及与以下疾病相关的疾病 炎症和氧化应激。 完成这些具体目标将 为基于人群的分子流行病学提供新的生物标志物 研究。 此类研究将提供旨在预防和 控制与炎症和氧化应激相关的人类疾病 可能发生在环境疾病中。